JAMA - Journal of the American Medical Association, ISSN 0098-7484, 02/2018, Volume 319, Issue 8, pp. 818 - 819
Is gabapentin associated with pain relief in people with chronic neuropathic pain? Oral gabapentin (1200-3600 mg/d for 4-12 weeks) for patients with moderate...
MEDICINE, GENERAL & INTERNAL | GUIDELINES | Analgesics - therapeutic use | Cyclohexanecarboxylic Acids - therapeutic use | Meta-Analysis as Topic | Off-Label Use | Administration, Oral | Humans | Cyclohexanecarboxylic Acids - adverse effects | Diabetic Neuropathies - drug therapy | Neuralgia, Postherpetic - drug therapy | Amines - therapeutic use | Amines - adverse effects | gamma-Aminobutyric Acid - therapeutic use | Analgesics - adverse effects | gamma-Aminobutyric Acid - adverse effects | Care and treatment | Dosage and administration | Paresthesia | Gabapentin | Drugs | Pain | Neuropathology | Pain management | Nervous system | Adults | Neuropathy
MEDICINE, GENERAL & INTERNAL | GUIDELINES | Analgesics - therapeutic use | Cyclohexanecarboxylic Acids - therapeutic use | Meta-Analysis as Topic | Off-Label Use | Administration, Oral | Humans | Cyclohexanecarboxylic Acids - adverse effects | Diabetic Neuropathies - drug therapy | Neuralgia, Postherpetic - drug therapy | Amines - therapeutic use | Amines - adverse effects | gamma-Aminobutyric Acid - therapeutic use | Analgesics - adverse effects | gamma-Aminobutyric Acid - adverse effects | Care and treatment | Dosage and administration | Paresthesia | Gabapentin | Drugs | Pain | Neuropathology | Pain management | Nervous system | Adults | Neuropathy
Journal Article
BMJ : British Medical Journal, ISSN 0959-8138, 5/2013, Volume 346, Issue 7911, pp. 19 - 21
Most analgesic drugs work well but in only a small percentage of people. Andrew Moore and colleagues argue that we need to move away from a focus on average...
Postherpetic neuralgia | Diabetic neuropathies | Health outcomes | Pain | Analgesics | Medical practice | Fibromyalgia | Clinical trials | Chronic diseases | ANALYSIS | Osteoarthritis | MEDICINE, GENERAL & INTERNAL | PREGABALIN | CHRONIC PAIN | FIBROMYALGIA | EFFICACY | POSTHERPETIC NEURALGIA | IMPROVEMENT | RANDOMIZED-TRIAL | PLACEBO-CONTROLLED TRIAL | ETORICOXIB | WITHDRAWAL | Analgesics - therapeutic use | Chronic Pain - drug therapy | Humans | Treatment Failure | Pain Management - methods | Pain Management - statistics & numerical data | Research Design
Postherpetic neuralgia | Diabetic neuropathies | Health outcomes | Pain | Analgesics | Medical practice | Fibromyalgia | Clinical trials | Chronic diseases | ANALYSIS | Osteoarthritis | MEDICINE, GENERAL & INTERNAL | PREGABALIN | CHRONIC PAIN | FIBROMYALGIA | EFFICACY | POSTHERPETIC NEURALGIA | IMPROVEMENT | RANDOMIZED-TRIAL | PLACEBO-CONTROLLED TRIAL | ETORICOXIB | WITHDRAWAL | Analgesics - therapeutic use | Chronic Pain - drug therapy | Humans | Treatment Failure | Pain Management - methods | Pain Management - statistics & numerical data | Research Design
Journal Article
JAMA, ISSN 0098-7484, 02/2016, Volume 315, Issue 8, pp. 813 - 814
CLINICAL QUESTION: Are topical nonsteroidal anti-inflammatory drugs (NSAIDs) associated with reduced pain intensity in acute musculoskeletal conditions, but...
Musculoskeletal Pain - drug therapy | Acute Pain - drug therapy | Humans | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Treatment outcome | Care and treatment | Anti-inflammatory drugs | Analysis | Dosage and administration | Myalgia | Risk factors | Musculoskeletal diseases | Nonsteroidal anti-inflammatory drugs | Clinical outcomes | Pain management
Musculoskeletal Pain - drug therapy | Acute Pain - drug therapy | Humans | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Treatment outcome | Care and treatment | Anti-inflammatory drugs | Analysis | Dosage and administration | Myalgia | Risk factors | Musculoskeletal diseases | Nonsteroidal anti-inflammatory drugs | Clinical outcomes | Pain management
Journal Article
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2012, Volume 2012, Issue 9, p. CD010111
Background Topical creams with capsaicin are used to treat pain from a wide range of chronic conditions including neuropathic pain. Following application to...
PHARMACOLOGICAL-TREATMENT | MEDICINE, GENERAL & INTERNAL | CHRONIC POSTHERPETIC NEURALGIA | GENERAL-POPULATION | MANAGEMENT | DOUBLE-BLIND | PERIPHERAL NEUROPATHY | PREVALENCE | OSTEOARTHRITIS | RANDOMIZED CLINICAL-TRIALS | DIABETIC-NEUROPATHY | Sensory System Agents - adverse effects | Chronic Pain - drug therapy | Drug Administration Schedule | Humans | Capsaicin - adverse effects | Sensory System Agents - administration & dosage | Adult | Administration, Topical | Neuralgia - drug therapy | Capsaicin - administration & dosage | Randomized Controlled Trials as Topic
PHARMACOLOGICAL-TREATMENT | MEDICINE, GENERAL & INTERNAL | CHRONIC POSTHERPETIC NEURALGIA | GENERAL-POPULATION | MANAGEMENT | DOUBLE-BLIND | PERIPHERAL NEUROPATHY | PREVALENCE | OSTEOARTHRITIS | RANDOMIZED CLINICAL-TRIALS | DIABETIC-NEUROPATHY | Sensory System Agents - adverse effects | Chronic Pain - drug therapy | Drug Administration Schedule | Humans | Capsaicin - adverse effects | Sensory System Agents - administration & dosage | Adult | Administration, Topical | Neuralgia - drug therapy | Capsaicin - administration & dosage | Randomized Controlled Trials as Topic
Journal Article
BMJ, ISSN 0959-8138, 11/2000, Volume 321, Issue 7270, pp. 1183 - 1187
Abstract Objectives: To assess the incidence of gastrointestinal haemorrhage associated with long term aspirin therapy and to determine the effect of dose...
Myocardial infarction | Gastrointestinal hemorrhage | Placebos | Experimentation | Strokes | Adverse effects | Dosage | Hemorrhage | Search strategies | Confidence interval | ACETYLSALICYLIC-ACID | MORTALITY | CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | PLACEBO | LOW-DOSE ASPIRIN | MYOCARDIAL-INFARCTION | EUROPEAN STROKE | SECONDARY PREVENTION | ADVERSE EVENTS | PROGRESSION | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Gastrointestinal Hemorrhage - chemically induced | Aspirin - adverse effects | Humans | Risk Factors | Fibrinolytic Agents - administration & dosage | Long-Term Care | Odds Ratio | Cyclooxygenase Inhibitors - adverse effects | Aspirin - administration & dosage | Randomized Controlled Trials as Topic | Papers
Myocardial infarction | Gastrointestinal hemorrhage | Placebos | Experimentation | Strokes | Adverse effects | Dosage | Hemorrhage | Search strategies | Confidence interval | ACETYLSALICYLIC-ACID | MORTALITY | CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | PLACEBO | LOW-DOSE ASPIRIN | MYOCARDIAL-INFARCTION | EUROPEAN STROKE | SECONDARY PREVENTION | ADVERSE EVENTS | PROGRESSION | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Gastrointestinal Hemorrhage - chemically induced | Aspirin - adverse effects | Humans | Risk Factors | Fibrinolytic Agents - administration & dosage | Long-Term Care | Odds Ratio | Cyclooxygenase Inhibitors - adverse effects | Aspirin - administration & dosage | Randomized Controlled Trials as Topic | Papers
Journal Article
BMC Geriatrics, ISSN 1471-2318, 2008, Volume 8, Issue 1, pp. 1 - 1
Ageing populations will impact on healthcare provision, especially since extra years are not necessarily spent in good health. It is important to identify and...
Anemia - classification | Prevalence | Age Factors | Anemia - epidemiology | Hospitalization - trends | Humans | Risk Factors | Anemia - diagnosis | Aged | Nursing Homes - trends | Cohort Studies | Research | Anemia | Health aspects | Risk factors
Anemia - classification | Prevalence | Age Factors | Anemia - epidemiology | Hospitalization - trends | Humans | Risk Factors | Anemia - diagnosis | Aged | Nursing Homes - trends | Cohort Studies | Research | Anemia | Health aspects | Risk factors
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 06/2006, Volume 126, Issue 6, pp. 1251 - 1255
Benefit and harm associated with treating actinic keratosis (AK) with the immune response modifier imiquimod was assessed using published randomized-controlled...
POPULATION | TESTS | PUBLICATION | QUALITY | SCALP | VEHICLE-CONTROLLED TRIALS | PARALLEL-GROUP | DOUBLE-BLIND | PREVALENCE | 5-PERCENT CREAM | DERMATOLOGY | Ointments - adverse effects | Carcinoma, Squamous Cell - drug therapy | Skin Neoplasms - drug therapy | Carcinoma in Situ - drug therapy | Ointments - therapeutic use | Antineoplastic Agents - adverse effects | Humans | Antineoplastic Agents - therapeutic use | Aminoquinolines - therapeutic use | Keratosis - drug therapy | Aminoquinolines - adverse effects | Randomized Controlled Trials as Topic
POPULATION | TESTS | PUBLICATION | QUALITY | SCALP | VEHICLE-CONTROLLED TRIALS | PARALLEL-GROUP | DOUBLE-BLIND | PREVALENCE | 5-PERCENT CREAM | DERMATOLOGY | Ointments - adverse effects | Carcinoma, Squamous Cell - drug therapy | Skin Neoplasms - drug therapy | Carcinoma in Situ - drug therapy | Ointments - therapeutic use | Antineoplastic Agents - adverse effects | Humans | Antineoplastic Agents - therapeutic use | Aminoquinolines - therapeutic use | Keratosis - drug therapy | Aminoquinolines - adverse effects | Randomized Controlled Trials as Topic
Journal Article
BMC Neurology, ISSN 1471-2377, 08/2008, Volume 8, Issue 1, pp. 29 - 29
Background: Duloxetine hydrochloride is a reuptake inhibitor of 5-hydroxytryptamine and norepinephrine used to treat depression, generalized anxiety disorder,...
COMPARING DULOXETINE | PLACEBO | MANAGEMENT | QUALITY | SAFETY | PHYSICAL SYMPTOMS | CLINICAL-TRIALS | DOUBLE-BLIND | MAJOR DEPRESSIVE DISORDER | ELDERLY-PATIENTS | CLINICAL NEUROLOGY | Fibromyalgia - complications | Thiophenes - therapeutic use | Adrenergic Uptake Inhibitors - therapeutic use | Humans | Treatment Outcome | Diabetic Neuropathies - drug therapy | Randomized Controlled Trials as Topic | Pain - drug therapy | Pain - physiopathology | Duloxetine Hydrochloride | Pain - etiology | Fibromyalgia - physiopathology | Diabetic Neuropathies - complications | Diabetic Neuropathies - physiopathology | Diabetic neuropathies | Research | Drug therapy | Risk factors | Chronic pain
COMPARING DULOXETINE | PLACEBO | MANAGEMENT | QUALITY | SAFETY | PHYSICAL SYMPTOMS | CLINICAL-TRIALS | DOUBLE-BLIND | MAJOR DEPRESSIVE DISORDER | ELDERLY-PATIENTS | CLINICAL NEUROLOGY | Fibromyalgia - complications | Thiophenes - therapeutic use | Adrenergic Uptake Inhibitors - therapeutic use | Humans | Treatment Outcome | Diabetic Neuropathies - drug therapy | Randomized Controlled Trials as Topic | Pain - drug therapy | Pain - physiopathology | Duloxetine Hydrochloride | Pain - etiology | Fibromyalgia - physiopathology | Diabetic Neuropathies - complications | Diabetic Neuropathies - physiopathology | Diabetic neuropathies | Research | Drug therapy | Risk factors | Chronic pain
Journal Article
BMC Musculoskeletal Disorders, ISSN 1471-2474, 2011, Volume 12, Issue 1, pp. 125 - 125
Background: Clinical trials in chronic pain often collect information about interference with work as answers to component questions of commonly used...
MODERATE | GENERAL-POPULATION | CLINICAL-TRIALS | DOUBLE-BLIND | DISABILITY | INTENSITY | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | OUTCOMES | PREVALENCE | RHEUMATOLOGY | ORTHOPEDICS | Humans | Middle Aged | Cost of Illness | Male | Absenteeism | Pregabalin | Activities of Daily Living | Young Adult | Time Factors | Pain - drug therapy | Fibromyalgia - drug therapy | Aged, 80 and over | Pain - etiology | Adult | Female | Surveys and Questionnaires | Retrospective Studies | gamma-Aminobutyric Acid - therapeutic use | Severity of Illness Index | Analgesics - therapeutic use | Fibromyalgia - complications | Treatment Outcome | Randomized Controlled Trials as Topic | Fibromyalgia - diagnosis | Pain - physiopathology | Adolescent | Aged | Fibromyalgia - physiopathology | Pain Measurement | gamma-Aminobutyric Acid - analogs & derivatives | Pain - diagnosis | Rheumatology | Interference | Clinical trials | Fibromyalgia | Diabetic neuropathy | Systematic review | Data processing | Fatigue | Arthritis | Patients | Quality of life | Validity | Pain | Questionnaires
MODERATE | GENERAL-POPULATION | CLINICAL-TRIALS | DOUBLE-BLIND | DISABILITY | INTENSITY | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | OUTCOMES | PREVALENCE | RHEUMATOLOGY | ORTHOPEDICS | Humans | Middle Aged | Cost of Illness | Male | Absenteeism | Pregabalin | Activities of Daily Living | Young Adult | Time Factors | Pain - drug therapy | Fibromyalgia - drug therapy | Aged, 80 and over | Pain - etiology | Adult | Female | Surveys and Questionnaires | Retrospective Studies | gamma-Aminobutyric Acid - therapeutic use | Severity of Illness Index | Analgesics - therapeutic use | Fibromyalgia - complications | Treatment Outcome | Randomized Controlled Trials as Topic | Fibromyalgia - diagnosis | Pain - physiopathology | Adolescent | Aged | Fibromyalgia - physiopathology | Pain Measurement | gamma-Aminobutyric Acid - analogs & derivatives | Pain - diagnosis | Rheumatology | Interference | Clinical trials | Fibromyalgia | Diabetic neuropathy | Systematic review | Data processing | Fatigue | Arthritis | Patients | Quality of life | Validity | Pain | Questionnaires
Journal Article
BMJ, ISSN 0959-8138, 04/2004, Volume 328, Issue 7446, pp. 991 - 994
Abstract Objective To determine the efficacy and safety of topically applied capsaicin for chronic pain from neuropathic or musculoskeletal disorders. Data...
Diabetic neuropathies | Pain | Response rates | Placebos | Experimentation | Musculoskeletal pain | Osteoarthritis | Primary care | Chronic pain | Confidence interval | Plasters | NEUROPATHIC PAIN | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | CREAM | DOUBLE-BLIND | RANDOMIZED CLINICAL-TRIALS | Humans | Capsaicin - adverse effects | Analgesics - administration & dosage | Treatment Outcome | Neuralgia - drug therapy | Capsaicin - administration & dosage | Randomized Controlled Trials as Topic | Pain - drug therapy | Pain - etiology | Pain Measurement | Administration, Topical | Chronic Disease | Analgesics - adverse effects | Musculoskeletal Diseases - complications | Primary Care
Diabetic neuropathies | Pain | Response rates | Placebos | Experimentation | Musculoskeletal pain | Osteoarthritis | Primary care | Chronic pain | Confidence interval | Plasters | NEUROPATHIC PAIN | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | CREAM | DOUBLE-BLIND | RANDOMIZED CLINICAL-TRIALS | Humans | Capsaicin - adverse effects | Analgesics - administration & dosage | Treatment Outcome | Neuralgia - drug therapy | Capsaicin - administration & dosage | Randomized Controlled Trials as Topic | Pain - drug therapy | Pain - etiology | Pain Measurement | Administration, Topical | Chronic Disease | Analgesics - adverse effects | Musculoskeletal Diseases - complications | Primary Care
Journal Article
Pain Practice, ISSN 1530-7085, 01/2014, Volume 14, Issue 1, pp. 79 - 94
Background Chronic pain is distressing for patients and a burden on healthcare systems and society. Recent research demonstrates different aspects of the...
evidence‐based medicine | neuropathic pain | pain disorder | health‐related quality of life | pain treatment | systematic review | noncancer pain | healthcare costs | Health-related quality of life | Healthcare costs | Pain treatment | Pain disorder | Noncancer pain | Systematic review | Evidence-based medicine | Neuropathic pain | LOW-BACK-PAIN | health-related quality of life | CLINICAL NEUROLOGY | ALL-CAUSE MORTALITY | GENERAL-POPULATION | SPINAL-CORD STIMULATION | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | WIDESPREAD BODY PAIN | CROSS-SECTIONAL SURVEY | DIABETIC PERIPHERAL NEUROPATHY | ANESTHESIOLOGY | QUALITY-OF-LIFE | evidence-based medicine | PRACTITIONERS ORAL-CONTRACEPTION | Chronic Pain - therapy | Health Care Costs | Humans | Pain Management - methods | Chronic Pain - economics | Neuralgia - economics | Neuralgia - therapy | Pain Management - economics | Care and treatment | Pain | Analysis | Chronic pain | Medical care, Cost of
evidence‐based medicine | neuropathic pain | pain disorder | health‐related quality of life | pain treatment | systematic review | noncancer pain | healthcare costs | Health-related quality of life | Healthcare costs | Pain treatment | Pain disorder | Noncancer pain | Systematic review | Evidence-based medicine | Neuropathic pain | LOW-BACK-PAIN | health-related quality of life | CLINICAL NEUROLOGY | ALL-CAUSE MORTALITY | GENERAL-POPULATION | SPINAL-CORD STIMULATION | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | WIDESPREAD BODY PAIN | CROSS-SECTIONAL SURVEY | DIABETIC PERIPHERAL NEUROPATHY | ANESTHESIOLOGY | QUALITY-OF-LIFE | evidence-based medicine | PRACTITIONERS ORAL-CONTRACEPTION | Chronic Pain - therapy | Health Care Costs | Humans | Pain Management - methods | Chronic Pain - economics | Neuralgia - economics | Neuralgia - therapy | Pain Management - economics | Care and treatment | Pain | Analysis | Chronic pain | Medical care, Cost of
Journal Article
12.
Full Text
Single dose oral ibuprofen plus paracetamol (acetaminophen) for acute postoperative pain
The Cochrane database of systematic reviews, ISSN 1469-493X, 2013, Volume 6, Issue 10, p. CD010210
Background Combining two different analgesics in fixed doses in a single tablet can provide better pain relief than either drug alone in acute pain. This...
RANDOMIZED CONTROLLED-TRIALS | MEDICINE, GENERAL & INTERNAL | INDIVIDUAL PATIENT METAANALYSIS | IMPACT | EFFICACY | CLINICAL-TRIALS | DOUBLE-BLIND | INTENSITY | COMBINATION | KETOROLAC | DICHOTOMOUS OUTCOME MEASURES | Acetaminophen - adverse effects | Acute Pain - drug therapy | Pain, Postoperative - drug therapy | Administration, Oral | Humans | Acetaminophen - administration & dosage | Ibuprofen - administration & dosage | Analgesics, Non-Narcotic - administration & dosage | Randomized Controlled Trials as Topic | Analgesics, Non-Narcotic - adverse effects | Adult | Ibuprofen - adverse effects | Drug Combinations
RANDOMIZED CONTROLLED-TRIALS | MEDICINE, GENERAL & INTERNAL | INDIVIDUAL PATIENT METAANALYSIS | IMPACT | EFFICACY | CLINICAL-TRIALS | DOUBLE-BLIND | INTENSITY | COMBINATION | KETOROLAC | DICHOTOMOUS OUTCOME MEASURES | Acetaminophen - adverse effects | Acute Pain - drug therapy | Pain, Postoperative - drug therapy | Administration, Oral | Humans | Acetaminophen - administration & dosage | Ibuprofen - administration & dosage | Analgesics, Non-Narcotic - administration & dosage | Randomized Controlled Trials as Topic | Analgesics, Non-Narcotic - adverse effects | Adult | Ibuprofen - adverse effects | Drug Combinations
Journal Article
BMC Musculoskeletal Disorders, ISSN 1471-2474, 2010, Volume 11, Issue 1, pp. 150 - 150
Background: Population mean changes are difficult to use in clinical practice. Responder analysis may be better, but needs validating for level of response and...
NEUROPATHIC PAIN | GENERAL-POPULATION | METAANALYSIS | CHRONIC PAIN | EFFICACY | CLINICAL-TRIALS | DOUBLE-BLIND | ENRICHED ENROLLMENT | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | RHEUMATOLOGY | ORTHOPEDICS | Outcome Assessment (Health Care) - methods | Humans | Middle Aged | Analgesics - administration & dosage | Male | Treatment Outcome | gamma-Aminobutyric Acid - administration & dosage | Pregabalin | Clinical Trials, Phase III as Topic - methods | Dose-Response Relationship, Drug | Young Adult | Multicenter Studies as Topic - methods | Fibromyalgia - drug therapy | Adolescent | Aged, 80 and over | Adult | Female | Clinical Trials, Phase II as Topic - methods | Fibromyalgia - physiopathology | Pain Measurement | gamma-Aminobutyric Acid - analogs & derivatives | Analgesics - adverse effects | gamma-Aminobutyric Acid - adverse effects
NEUROPATHIC PAIN | GENERAL-POPULATION | METAANALYSIS | CHRONIC PAIN | EFFICACY | CLINICAL-TRIALS | DOUBLE-BLIND | ENRICHED ENROLLMENT | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | RHEUMATOLOGY | ORTHOPEDICS | Outcome Assessment (Health Care) - methods | Humans | Middle Aged | Analgesics - administration & dosage | Male | Treatment Outcome | gamma-Aminobutyric Acid - administration & dosage | Pregabalin | Clinical Trials, Phase III as Topic - methods | Dose-Response Relationship, Drug | Young Adult | Multicenter Studies as Topic - methods | Fibromyalgia - drug therapy | Adolescent | Aged, 80 and over | Adult | Female | Clinical Trials, Phase II as Topic - methods | Fibromyalgia - physiopathology | Pain Measurement | gamma-Aminobutyric Acid - analogs & derivatives | Analgesics - adverse effects | gamma-Aminobutyric Acid - adverse effects
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2015, Volume 9, Issue 10, p. CD008659
Background This is an updated version of the original Cochrane overview published in Issue 9, 2011. That overview considered both efficacy and adverse events,...
Tooth Extraction [adverse effects] | MEDICINE, GENERAL & INTERNAL | Administration, Oral | Review Literature as Topic | Humans | Adult | Analgesics [administration & dosage; adverse effects] | Pain, Postoperative [drug therapy] | Acute Pain - drug therapy | Pain, Postoperative - drug therapy | Analgesics - administration & dosage | Analgesics - adverse effects
Tooth Extraction [adverse effects] | MEDICINE, GENERAL & INTERNAL | Administration, Oral | Review Literature as Topic | Humans | Adult | Analgesics [administration & dosage; adverse effects] | Pain, Postoperative [drug therapy] | Acute Pain - drug therapy | Pain, Postoperative - drug therapy | Analgesics - administration & dosage | Analgesics - adverse effects
Journal Article